A randomised phase III study on the treatment of children and adolescents with refractory or relapsed acutye myeloid leukemia (AML).
Phase of Trial: Phase III
Latest Information Update: 04 Apr 2013
At a glance
- Drugs Daunorubicin liposomal (Primary) ; Cytarabine; Doxorubicin liposomal; Filgrastim; Fludarabine; Granulocyte colony-stimulating factors
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 14 Jan 2013 Primary endpoint 'Haematological-response-rate' has been met.
- 11 Nov 2010 Last checked against Netherlands Trial Register record.
- 18 Dec 2009 Status changed from active, no longer recruiting to completed.